Pages

.

Showing posts with label Newly. Show all posts
Showing posts with label Newly. Show all posts

Newly Launched Secure Identity & Biometrics Association (SIBA) Provides Innovative Solutions to Often Complex Security and Identity Protection Issues

Janice Kephart, SIBA CEO and founder. (PRNewsFoto/Secure Identity & Biometrics Association (SIBA))jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";WASHINGTON, Feb. 7, 2014 /PRNewswire/ -- A new association designed to bring the "A" game to identity-thought leadership, the Secure Identity & Biometrics Association (SIBA), debuts today. SIBA was created for vendors, research institutions, nonprofits and individuals. The organization's purpose is to provide proactive education, policy refinement and solutions to the complexities of balancing identity security and protection with national security, public safety, economic strength, privacy and innovation. These technologies include both biological and behavioral biometrics such as fingerprints, facial and iris recognition, voice identification as well as secure credentials.  

(Photo: http://photos.prnewswire.com/prnh/20140207/PH60834-a )

(Logo: http://photos.prnewswire.com/prnh/20140207/PH60834LOGO-b )

Today these technologies make the world more physically and virtually safe, quick, and economically efficient. Benefits include securing borders, enabling individuals without documentation to be brought out of anonymity, catching dangerous criminals and terrorists, reconciling refugees and reuniting families, reducing identity theft, and enabling medical patients increased privacy while reducing fraud in healthcare. For consumers, biometrics provide protection beyond the use of passwords, most tangibly in banking and mobile solutions.  

Yet SIBA believes that even greater benefits from these innovations can be realized if we understand better what these technologies are, and are not, and how they truly affect us as individuals, a nation, and as a global community. "With a struggling economy, the opportunity for innovation and economic growth is explosive. The global biometrics market was $7 billion in 2012. By 2020, it is slated to grow to $20 billion. With policies in place that embrace responsible future applications, these technologies can evolve into a core stabilizer for the economy's recovery and future growth," said SIBA founder and CEO, Janice Kephart.

Kephart has garnered success in some of the most difficult environments in Washington, D.C. bringing to SIBA unprecedented leadership and know-how. Ms. Kephart has:

supported and drafted identity-related recommendations in the 9/11 Final Report as a border counsel to the 9/11 Commission and is a key author of the Commission staff monograph, 9/11 and Terrorist Travel; testified 16 times before Congress on issues including identity legislation and policy; had two bills pass Congress by unanimous consent and signed into law including the current federal criminal code for identity theft; spent five years as a think tank national security director; consulted for the Department of Homeland Security on secure credential law; appeared at conferences, and dozens of appearances on major TV, radio and print media outlets as both expert and opinion writer; hosted "The Homeland Security Show with Janice Kephart" on VIPInternetRadio.com which aired for an hour every Monday for a year and a half, the most listened to show on the station; has been featured by Duke University as one of the most influential undergraduate alums of the 1980s. For more, see http://www.sibassoc.org/ or contact jkephart@sibassoc.org For membership inquiries: mmontgomery@sibassoc.org Read Kephart's new backgrounder on why biometric exit may advance in 2014 with or without immigration reform here.Contact:
Janice Kephart
703-581-7721

Read more news from Secure Identity & Biometrics Association.

SOURCE Secure Identity & Biometrics Association (SIBA)

reade more... Résuméabuiyad

Garcinia Ex, a Garcinia Cambogia Extract Review Company, Launches its Newly Updated Website

Garcinia Ex, a Garcinia Cambogia Extract Review Company, Launches its Newly Updated Website. (PRNewsFoto/Garcinia Ex)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";LOS ANGELES, Jan. 17, 2014 /PRNewswire-iReach/ -- Garcinia Ex, a company that features educational and in-depth Garcinia Cambogia Extract reviews, has just launched its newly revised website. The site now features links to new and updated content and Garcinia Cambogia products.

(Photo: http://photos.prnewswire.com/prnh/20140117/MN48331)

While many people want to find out if Garcinia Cambogia can truly help them lose weight, it can be difficult to decide which brand of extract they should purchase. Thanks to the many Garcinia Cambogia reviews—which include information on the Top 5 Extracts that are available in Canada, New Zealand, Australia, the United Kingdom, and other countries—shoppers can rest easy, knowing that they are purchasing a top quality Garcinia Cambogia product.

As an article on the Garcinia Ex website explains, the main ingredient in Garcinia Cambogia supplements is called Hydroxycitric Acid, or HCA. This derivative of citric acid is found in tropical plants. Generally speaking, the article said, Garcinia Cambogia capsules that contain 60 percent HCA are the most beneficial for weight loss.

"The fact is that most Garcinia Cambogia extracts do not come from the same source proven effective in clinical studies," the article noted, adding that in addition, most supplements are not the correct dosage, and do not include enough HCA to make a difference.

"Hundreds of Fly-by-night supplement makers are rushing to create their own product and 'cash-in' on this huge diet. So before you buy, make sure the Garcinia Cambogia extract you choose meets all the criteria."

In addition, while some dietary supplements come with unwanted and unpleasant side effects, since Garcinia Cambogia is made from all natural ingredients, its only known side effect is weight loss.

People who would like to lose weight and want to learn more about Garcinia Cambogia are welcome to visit the newly-updated Garcinia Ex website; there, they can browse through the new information that is part of the site's Garcinia Cambogia launch, as well as what shoppers need to know when they are purchasing the product. Visitors to the site may also click on links that will take them to another website where they can purchase high quality Garcinia Cambogia.

About Garcinia Ex:

Garcinia Ex is a company that researches health supplements that meet specifications within the industry. The researched products are listed on the company's website for the public to learn more about. Garcinia Ex also takes in suggestions from the public for new supplements on the market to conduct research on. For more information, please visit http://garciniaex.com/

Media Contact: Jessie Dean, Garcinia Ex, 480 243-8054, admin@rocketfactor.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Garcinia Ex

reade more... Résuméabuiyad

Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action

Robbins Arroyo LLP. (PRNewsFoto/Robbins Arroyo LLP)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Vical Incorporated (NASDAQ: VICL) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of California.  The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between February, 8, 2012 and August 12, 2013 (the "Class Period").  Vical engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. Vical's lead drug candidate, Allovectin, is a Phase 3 clinical trial product to treat metastatic melanoma.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Vical Accused of Misleading Investors Regarding Its Ability to Obtain FDA Approval for Allovectin

Shares of Vical fell $2.05, or 57%, to close at $1.53 on August 12, 2013, after the company announced that the top-line results from the company's Phase 3 trial of Allovectin failed to demonstrate a significant improvement over chemotherapy.

According to the complaint, the company made false and misleading statements and/or failed to disclose material adverse facts about the company's business prospects and financial condition. Specifically, the complaint alleges that, throughout the Class Period, Vical misled investors about the efficacy of Allovectin and the likelihood of its success in the Phase 3 trial.  Further, the complaint alleges that the company deliberately delayed the announcement of the results of the Allovectin trial to avoid revealing the truth to the market.

Vical Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in Vical and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: http://www.robbinsarroyo.com/shareholders-rights-blog/vical-incorporated/

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

SOURCE Robbins Arroyo LLP

RELATED LINKS
http://www.robbinsarroyo.com

reade more... Résuméabuiyad